|
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma Clinical research trials and Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma. Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma clinical trial. Human subjects often obtain the finest healthcare possible for their Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma  Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma
For Condition: primary central nervous system lymphoma
Status: No longer recruiting
Sponsor(s): EORTC Lymphoma Cooperative Group ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of methotrexate and cytarabine plus radiation therapy in treating patients who have primary CNS lymphoma.
Details: OBJECTIVES: I. Determine the efficacy of methotrexate and cytarabine chemotherapy in combination with whole-brain radiation therapy for patients with non-AIDS related primary central nervous system lymphoma. II. Assess the response rate and safety of this chemotherapy regimen. PROTOCOL OUTLINE: Patients receive the first course of chemotherapy as soon as possible after diagnosis and staging. Methotrexate (MTX) IV is administered over 40-60 minutes on days 1 and 15. Cytarabine (AraC) is administered intrathecally on days 1 and 15. The second course of chemotherapy begins on day 29 or after bone marrow recovery. Radiation therapy begins no later than 3 weeks after completing chemotherapy. Patients are followed until death. PROJECTED ACCRUAL: A maximum of 50 patients will be accrued.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 16 Years/60 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven non-Hodgkin's lymphoma of the central nervous system (CNS) including leptomeninges and the spinal cord - No Burkitt's lymphoma or low grade T-cell lymphoma - Must have at least 1 measurable lesion - No AIDS-related primary central nervous system lymphoma (PCNSL) - No disease confined to the eye without other localization in the CNS --Prior/Concurrent Therapy-- - Biologic therapy: No concurrent treatment with immunosuppressive drug - Chemotherapy: No prior chemotherapy - Endocrine therapy: Corticosteroid use for less than 3 weeks allowed - Radiotherapy: Not specified - Surgery: No prior organ transplantation --Patient Characteristics-- - Age: 16 to 60 - Performance status: Karnofsky 40-100%; Neurological functional status 0-3 - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: No serious impairment of hepatic function - Renal: No serious impairment of renal function; Creatinine no greater than 1.5 mg/dL OR Creatinine clearance no less than 50 mL/min - Cardiovascular: No serious impairment of cardiac function - Other: HIV negative; No congenital or acquired immunodeficiency syndrome; No prior/concurrent systemic lymphoma; No prior malignancy except: Adequately treated non-melanoma skin cancer; Carcinoma in situ of the cervix uteri; Not pregnant; No severe uncontrolled infection
Total Enrollment:
Location and Contact Information:
Overall Study Official:
PatriceCarde, Study Chair, EORTC Lymphoma Cooperative Group
Rotterdam Cancer Institute
Rotterdam, , 3075 EA
Netherlands
Academisch Ziekenhuis Maastricht
Maastricht, , 6202 AZ
Netherlands
Academisch Ziekenhuis Utrecht
Utrecht, , 3508 GA
Netherlands
Institut Gustave Roussy
Villejuif, , F-94805
France
U.Z. Gasthuisberg
Leuven, , B-3000
Belgium
Dr. Bernard Verbeeten Instituut
Tilburg, , 5042 SB
Netherlands
Atrium Medical Centre
HEERLEN, , 6419 PC
Netherlands
Additional Information:
Study ID Numbers: CDR0000065724; EORTC-20962
Study Start Date: July 1997
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003061
Other Primary Central Nervous System Lymphoma Studies:
1. Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
2. Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma
3. Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma
4. Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
5. Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma
Related Studies:
Other primary central nervous system lymphoma Clinical Trials
Other Clinical Trials
Other HEERLEN Clinical Trials
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma
|
|
|
|
|
|
|
|
